Patent assignee · BE · COMPANY

IMCYSE SA

11Patents
11Active
11Granted
51Portfolio score

Filing activity: Feb 14, 2008 → Jun 30, 2022 · 1 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US9394517B2 CD4+ T-cells with cytolytic properties Chemistry; Metallurgy 14 Active
US9248171B2 Immunogenic peptides and their use in transplantation Chemistry; Metallurgy 14 Active
US10808016B2 Peptides and methods for the treatment of diabetes Human Necessities 3 Active
US11485768B2 Immunogenic CD1d binding peptides Human Necessities 2 Active
US11407795B2 Peptides and methods for the treatment of diabetes Human Necessities 2 Active
US11226332B2 Method for the detection, preparation and depletion of CD4+ t lymphocytes Physics 2 Active
US10729791B2 Animal models for evaluating pharmaceutical compounds Human Necessities 2 Active
US11787849B2 Methods and compounds for eliminating immune responses to therapeutic agents Chemistry; Metallurgy 0 Active
US11718650B2 Immunogenic peptides and their use in immune disorders Chemistry; Metallurgy 0 Active
US12023384B2 Immunogenic peptides comprising an MHC class II T cell epitope and a redox motif Human Necessities 0 Active
US11760782B2 Peptides and methods for the treatment of diabetes Human Necessities 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.